Urticaria (Hives)

1. Clinical Overview

Summary

Urticaria (hives) is a common heterogeneous condition characterised by transient, intensely pruritic wheals (raised, erythematous, oedematous lesions) resulting from mast cell degranulation and histamine release in the superficial dermis. Individual wheals are typically fleeting, resolving within 24 hours without residual marks, distinguishing urticaria from urticarial vasculitis. The condition is classified by duration: Acute Urticaria (less than 6 weeks, often allergic, infectious, or drug-induced) and Chronic Urticaria (≥6 weeks), with the latter subdivided into Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). [1,2]

CSU, representing approximately 70% of chronic cases, is frequently driven by autoimmune mechanisms involving autoantibodies against the high-affinity IgE receptor (FcεRI) or IgE itself. [3] Angioedema, affecting deeper dermal and submucosal tissues, accompanies urticaria in approximately 40-50% of cases and requires urgent evaluation for airway compromise. [4]

First-line treatment consists of non-sedating H1-antihistamines (cetirizine, fexofenadine, loratadine), with dose escalation up to 4× licensed dose recommended for refractory cases before advancing therapy. [5,6] Omalizumab (anti-IgE monoclonal antibody) demonstrates remarkable efficacy (70-80% response rate) in antihistamine-refractory CSU and represents the gold standard second-line therapy. [7,8] Always exclude anaphylaxis in acute presentations with systemic features (hypotension, bronchospasm, severe angioedema). [9]

Clinical Pearls

Transient Wheals (less than 24h Each): Individual lesions resolving within 24 hours is pathognomonic. If wheals persist > 24 hours, are painful, or leave purpura/hyperpigmentation, consider urticarial vasculitis—a distinct entity requiring skin biopsy and investigation for systemic disease.

Chronic = Usually Autoimmune (CSU): Chronic spontaneous urticaria is predominantly autoimmune, with 30-50% of patients having autoantibodies against FcεRI or IgE. No external trigger is identified.

4× Antihistamine Dose is Evidence-Based: Standard dosing provides inadequate symptom control in most patients. International guidelines endorse quadrupling the dose before escalating to biologics. [5,6]

Omalizumab Works Exceptionally Well: Anti-IgE therapy achieves complete response in 40-50% and partial response in an additional 25-30% of CSU patients refractory to high-dose antihistamines. [7,8]

Autologous Serum Skin Test (ASST): This bedside test identifies autoimmune CSU by injecting the patient's own serum intradermally. A positive wheal-and-flare response suggests functional autoantibodies.

UAS7 Score: The Urticaria Activity Score (0-6 daily: 0-3 wheals, 0-3 pruritus) summed over 7 days (range 0-42) provides standardised severity assessment for CSU. UAS7 > 28 indicates severe disease.

---

2. Epidemiology

Prevalence and Incidence

• Lifetime Prevalence: Approximately 15-25% of the population experiences at least one episode of urticaria. [1,10]
• Acute Urticaria: Accounts for ~70-80% of all urticaria cases. Peak incidence in young adults and children.
• Chronic Urticaria: Point prevalence ~0.5-1% of the general population. [11]
• Gender: Chronic urticaria demonstrates female predominance (2:1), particularly CSU. Acute urticaria shows no significant sex difference.
• Age: Can occur at any age. CSU typically affects adults aged 30-50 years.

Classification

Chronic Inducible Urticaria (CIndU) Subtypes

Burden of Disease

• Quality of Life Impact: CSU profoundly affects quality of life, comparable to coronary artery disease or severe ischaemic heart disease in validated measures (DLQI scores). [11]
• Economic Burden: Significant direct (consultations, medications) and indirect (work absenteeism) costs. Chronic urticaria results in mean productivity loss of 4-8 hours/week.
• Comorbidities: Strong association with thyroid autoimmunity (12-29%), coeliac disease, type 1 diabetes, rheumatoid arthritis, and psychiatric comorbidity (anxiety, depression). [3]

---

3. Aetiology and Pathophysiology

Molecular Mechanisms of Mast Cell Activation

Exam Detail: Mast Cell Degranulation Pathway:

1. Sensitisation: IgE antibodies bind to high-affinity FcεRI receptors on mast cell surface.
2. Triggering: Allergen cross-links surface-bound IgE molecules → FcεRI aggregation.
3. Signal Transduction: FcεRI aggregation activates intracellular tyrosine kinases (Lyn, Syk, Bruton's tyrosine kinase [BTK]) → phosphorylation cascades.
4. Calcium Influx: Signalling increases intracellular Ca²⁺ via store-operated calcium entry (SOCE).
5. Degranulation: Ca²⁺ triggers fusion of cytoplasmic granules with plasma membrane → release of preformed mediators.
6. Mediator Synthesis: Arachidonic acid metabolism generates newly synthesised mediators (prostaglandins, leukotrienes).

Key Mediators and Effects:

Chronic Spontaneous Urticaria: Autoimmune Mechanisms

CSU is increasingly recognised as a mast cell-driven autoimmune disease. [3] Two distinct autoimmune endotypes exist:

Type I Autoimmune CSU (~35-40% of CSU)

• Pathomechanism: IgG autoantibodies directed against IgE itself (anti-IgE autoantibodies).
• Effect: These IgG antibodies bind to IgE already attached to mast cell FcεRI receptors, causing receptor cross-linking and degranulation.

Type IIb Autoimmune CSU (~5-10% of CSU)

• Pathomechanism: IgG autoantibodies against the α-subunit of FcεRI (anti-FcεRI autoantibodies).
• Effect: Direct cross-linking of FcεRI receptors → mast cell activation without requirement for IgE.
• Evidence: Serum from these patients induces histamine release from basophils and mast cells of healthy donors (basophil activation test, basophil histamine release assay).

Autologous Serum Skin Test (ASST)

• Procedure: Intradermal injection of 0.05 mL autologous serum alongside negative (saline) and positive (histamine) controls.
• Positive Result: Wheal diameter ≥1.5 mm larger than saline control at 30 minutes.
• Interpretation: Indicates presence of functional histamine-releasing autoantibodies (sensitivity ~70%, specificity ~80%).
• Limitations: Positive ASST doesn't distinguish between anti-IgE and anti-FcεRI antibodies; can be positive due to histamine-releasing factors other than IgG autoantibodies.

Why Omalizumab Works in CSU

Omalizumab (anti-IgE mAb) achieves efficacy through multiple mechanisms: [7]

1. Reduces free IgE: Binds circulating IgE, preventing IgE-FcεRI interaction.
2. Downregulates FcεRI: Chronic reduction in free IgE leads to downregulation of FcεRI expression on mast cells and basophils (50-97% reduction).
3. Removes autoantibody targets: In Type I autoimmune CSU, omalizumab removes IgE from mast cell surface, eliminating targets for anti-IgE autoantibodies.
4. Increases activation threshold: Fewer FcεRI receptors require stronger stimuli for degranulation.

Chronic Inducible Urticaria Mechanisms

Physical urticarias involve distinct pathways:

• Symptomatic Dermographism: Mechanical shear stress → direct mast cell degranulation (non-immunologic).
• Cold Urticaria: Cold-induced membrane reorganisation → mast cell activation. Rewarming triggers maximal histamine release. Associated with cryoproteins or cold agglutinins in some cases.
• Cholinergic Urticaria: Sweating → cholinergic nerve stimulation → acetylcholine release → mast cell degranulation via muscarinic receptors. Reduced sweat gland density observed in some patients.
• Delayed Pressure Urticaria: Sustained pressure → inflammatory infiltrate (neutrophils, eosinophils) → late-phase oedema. Cytokine-mediated rather than immediate histamine release.
• Solar Urticaria: Photons activate chromophores → photoallergen formation → IgE-mediated or direct mast cell activation. Action spectrum (wavelengths causing reaction) varies individually.

Associated Conditions

• Thyroid Autoimmunity: Anti-thyroid peroxidase (anti-TPO) or anti-thyroglobulin antibodies present in 12-29% of CSU patients, even with normal thyroid function. Shared autoimmune diathesis. [3]
• Helicobacter pylori: Controversial association. Eradication occasionally improves CSU in subset of patients, but systematic reviews show inconsistent benefit.
• Chronic Infections: Occult infections (dental, sinus, urinary) occasionally implicated, but routine investigation not recommended without clinical indication.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Can precipitate or exacerbate urticaria via COX-1 inhibition → leukotriene overproduction. Affects 20-30% of CSU patients. Non-acetylated salicylates or COX-2 selective inhibitors may be tolerated.

---

4. Differential Diagnosis

Key Differentiating Features

When to Suspect Urticarial Vasculitis

Urticarial vasculitis is a distinct clinicopathologic entity characterised by histologic vasculitis presenting with urticarial lesions. [12]

Diagnostic Criteria (American College of Rheumatology):

• Urticaria-like lesions present for ≥6 months.
• Skin biopsy: leukocytoclastic vasculitis.

Clues Suggesting Urticarial Vasculitis (vs. Simple Urticaria):

• Individual lesions persist > 24 hours (up to 3 days).
• Lesions are painful, tender, or burning (not predominantly pruritic).
• Leave purpura, ecchymoses, or post-inflammatory hyperpigmentation.
• Systemic features: arthralgia/arthritis, fever, abdominal pain, elevated ESR/CRP.
• Hypocomplementaemia (low C3, C4) in hypocomplementaemic urticarial vasculitis (HUV).
• Associated with SLE, Sjögren's syndrome, hepatitis B/C, malignancy.

Investigations for Suspected Urticarial Vasculitis:

• Skin biopsy (lesion less than 24h old): leukocytoclastic vasculitis (fibrinoid necrosis of vessel walls, neutrophilic infiltrate, extravasated RBCs).
• Complement levels: C3, C4, CH50.
• Autoimmune screen: ANA, ENA, anti-dsDNA (SLE screen).
• Infectious screen: Hepatitis B/C serology.
• Urinalysis: Proteinuria/haematuria (renal involvement in systemic vasculitis).

---

5. Clinical Presentation

Symptoms

Wheals (The Hallmark)

Angioedema

Present in 40-50% of urticaria cases. [4]

• Definition: Non-pitting swelling of deeper dermis, subcutaneous tissue, or submucosa.
• Sites: Lips, periorbital regions, tongue, uvula, genitalia, hands, feet. Visceral angioedema (bowel) → abdominal pain, nausea, vomiting, diarrhoea.
• Sensation: Tightness, discomfort, or burning rather than pruritus.
• Duration: Typically resolves within 48-72 hours (longer than wheals).
• Airway Risk: Laryngeal angioedema (dysphonia, dysphagia, stridor, dyspnoea) is a medical emergency requiring immediate treatment and airway assessment.

Angioedema without Urticaria is a separate diagnostic category:

• Hereditary Angioedema (HAE): C1-esterase inhibitor deficiency (quantitative [Type I] or functional [Type II]) or factor XII mutation (Type III). Recurrent non-pruritic angioedema, often triggered by trauma/stress. Bradykinin-mediated (antihistamines and adrenaline ineffective). Diagnosis: low C4 (screening), low C1-INH level/function. [13]
• ACE Inhibitor-Induced: Can occur weeks to years after starting ACE inhibitor. Bradykinin accumulation. Switching to ARB not always safe (10% cross-reactivity).
• Acquired C1-Esterase Inhibitor Deficiency: Consumption (lymphoproliferative disorders) or autoantibodies. Low C1q distinguishes from hereditary forms.

History: Key Questions

1. Timing and Duration:

   • How long have you had symptoms? (Acute less than 6 weeks vs. Chronic ≥6 weeks)
   • How long does each individual wheal last? (less than 24h is typical urticaria; > 24h suggests vasculitis)

2. Triggers and Pattern:

   • Any identifiable triggers? Food, medications, infections, physical factors (cold, heat, pressure, sunlight, exercise)?
   • Any temporal pattern? Worse at certain times of day? Related to activities?

3. Associated Symptoms:

   • Any swelling of lips, tongue, or throat? Difficulty breathing or swallowing? (Angioedema/anaphylaxis)
   • Any systemic symptoms: dizziness, chest tightness, wheeze, abdominal pain, diarrhoea? (Anaphylaxis)
   • Fever, joint pain, or abdominal pain? (Urticarial vasculitis, systemic disease)

4. Drug History:

   • Recent medications? Antibiotics (penicillins, sulfonamides), NSAIDs, ACE inhibitors?
   • NSAIDs can exacerbate urticaria in 20-30% of CSU patients.

5. Infection History:

   • Recent viral illness? (Common trigger for acute urticaria, especially children)
   • Dental problems, sinusitis, UTI? (Rarely contributory, but consider in refractory cases)

6. Medical History:

   • Thyroid disease or autoimmune conditions?
   • Atopic history (asthma, allergic rhinitis, eczema)? Suggests atopic diathesis, but CSU itself is not IgE-mediated against environmental allergens.
   • Family history of urticaria, angioedema, or autoimmune disease?

7. Quality of Life Impact:

   • Sleep disturbance? Work/school absenteeism? Psychological impact? (CSU profoundly affects QoL)

Examination Findings

Skin Examination

• Active Wheals: Raised oedematous plaques, blanching erythema, often with central pallor. Annular or serpiginous patterns.
• Dermographism Test: Stroke skin firmly with tongue depressor or pen. Positive if linear wheal develops within 5 minutes (indicates symptomatic dermographism—a CIndU subtype).
• Absence of Scarring/Pigmentation: Resolved lesions leave no trace (helps exclude urticarial vasculitis, which leaves purpura or hyperpigmentation).

Angioedema Assessment

• Inspect lips, tongue, periorbital areas, hands, feet for non-pitting swelling.
• Airway Assessment: Check for uvular oedema, tongue swelling. Ask about dysphagia, dysphonia. Listen for stridor. Assess respiratory rate and oxygen saturation.

Signs of Alternative Diagnoses

• Purpura or petechiae: Suggests vasculitis.
• Target lesions: Erythema multiforme.
• Vesicles or bullae: Consider bullous pemphigoid, pemphigus, dermatitis herpetiformis.
• Fixed pigmented lesions with Darier's sign: Urticaria pigmentosa (mastocytosis).

---

6. Investigations

Acute Urticaria (less than 6 Weeks)

Generally, no investigations are required. [5,6]

• Diagnosis is clinical: History and fleeting wheals.
• Identify trigger: Detailed history (foods, medications, infections). Allergen-specific IgE testing only if clear history suggests specific allergen (e.g., peanut, penicillin).
• Most cases are self-limiting: Resolve spontaneously.

Indications for Investigation in Acute Urticaria:

• Severe or recurrent episodes.
• Features of anaphylaxis.
• Suspected food or drug allergy requiring confirmation.

Chronic Urticaria (≥6 Weeks)

Baseline Investigations (All Chronic Urticaria)

Extended Investigations (Selected Cases)

Provocation Tests for Chronic Inducible Urticaria (CIndU)

Important: Provocation tests should be performed cautiously. Cold and exercise provocation carry anaphylaxis risk—ensure resuscitation equipment available.

UAS7 Score (Urticaria Activity Score)

The UAS7 is a validated patient-reported outcome for CSU severity assessment. [15]

Daily Scoring (0-6 points):

• Wheals (0-3 points):

  • 0: None
  • 1: Mild (less than 20 wheals/24h)
  • 2: Moderate (20-50 wheals/24h)
  • 3: Severe (> 50 wheals/24h or large confluent areas)

• Pruritus Intensity (0-3 points):

  • 0: None
  • 1: Mild (present but not annoying or troublesome)
  • 2: Moderate (troublesome but does not interfere with normal daily activity or sleep)
  • 3: Severe (sufficiently troublesome to interfere with normal daily activity or sleep)

Weekly Total (sum of 7 daily scores): 0-42

• 0: Urticaria-free
• 1-6: Well-controlled
• 7-15: Mild
• 16-27: Moderate
• 28-42: Severe

Clinical Use:

• Baseline assessment before treatment.
• Monitor response to therapy (target: UAS7 less than 7 or complete control [UAS7 = 0]).
• Determines need for treatment escalation.

---

7. Management

Management Algorithm

           URTICARIA PRESENTATION
                      ↓
          EXCLUDE ANAPHYLAXIS
     (Systemic features: hypotension, bronchospasm, 
      severe angioedema, GI symptoms?)
          ┌──────────┴──────────┐
         YES                   NO
          ↓                     ↓
    ANAPHYLAXIS            ASSESS DURATION
    PROTOCOL                & CLASSIFICATION
    - IM Adrenaline        
      500 mcg (0.5 mL 1:1000)    ┌────────────┴────────────┐
    - ABCDE Assessment          ACUTE (less than 6 weeks)      CHRONIC (≥6 weeks)
    - High-flow O₂                     ↓                     ↓
    - IV Fluids                  Often self-limiting    Classify subtype:
    - H1 + H2 Antihistamines      Identify & avoid     - CSU (spontaneous)
    - Hydrocortisone 200mg IV       trigger            - CIndU (inducible)
    - Monitor 4-6h (biphasic)    Symptomatic Rx       Often coexist (35-50%)
    - Discharge with AAI             ↓
      (adrenaline auto-injector)      ↓
                                      ↓
          ┌─────────────────────────────────────────────┐
          │  FIRST-LINE: NON-SEDATING H1-ANTIHISTAMINES │
          │  (sgAH: Second-Generation Antihistamines)   │
          ├─────────────────────────────────────────────┤
          │  Choose one:                                │
          │  • Cetirizine 10 mg OD                      │
          │  • Fexofenadine 180 mg OD                   │
          │  • Loratadine 10 mg OD                      │
          │  • Bilastine 20 mg OD                       │
          │  • Desloratadine 5 mg OD                    │
          │  • Levocetirizine 5 mg OD                   │
          │                                             │
          │  Review after 2-4 weeks                     │
          └─────────────────────────────────────────────┘
                      ↓
          INADEQUATE CONTROL? (UAS7 ≥7)
                      ↓
          ┌─────────────────────────────────────────────┐
          │  ESCALATE: UP TO 4× STANDARD DOSE           │
          │  (Off-label but guideline-endorsed) [5,6]   │
          ├─────────────────────────────────────────────┤
          │  Examples:                                  │
          │  • Cetirizine 10 mg QDS (40 mg/day)         │
          │  • Fexofenadine 180 mg BD or QDS            │
          │  • Levocetirizine 5 mg BD (20 mg/day)       │
          │                                             │
          │  Continue 2-4 weeks at maximum dose         │
          └─────────────────────────────────────────────┘
                      ↓
          STILL INADEQUATE CONTROL? (UAS7 ≥7)
                      ↓
          ┌─────────────────────────────────────────────┐
          │  SECOND-LINE: ADD OMALIZUMAB                │
          │  (Gold standard for antihistamine-          │
          │   refractory CSU) [7,8]                     │
          ├─────────────────────────────────────────────┤
          │  Dosing:                                    │
          │  • Omalizumab 300 mg SC every 4 weeks       │
          │  • Licensed for CSU in patients ≥12 years   │
          │  • Response typically within 1-4 weeks      │
          │  • 70-80% achieve control                   │
          │                                             │
          │  Specialist initiation (Dermatology/Allergy)│
          │  Continue sgAH during omalizumab therapy    │
          └─────────────────────────────────────────────┘
                      ↓
          INADEQUATE RESPONSE TO OMALIZUMAB?
          (10-30% of patients)
                      ↓
          ┌─────────────────────────────────────────────┐
          │  THIRD-LINE OPTIONS (Specialist)            │
          ├─────────────────────────────────────────────┤
          │  • INCREASE Omalizumab to 450-600 mg/4wks   │
          │    (off-label, limited evidence)            │
          │                                             │
          │  • CICLOSPORIN 3-5 mg/kg/day in 2 doses     │
          │    (off-label; significant side effects)    │
          │    Effective in 60-70% refractory cases     │
          │    Monitor BP, renal function, lipids       │
          │                                             │
          │  • EMERGING THERAPIES:                      │
          │    - Remibrutinib (BTK inhibitor) [16]      │
          │    - Dupilumab (anti-IL-4Rα; limited data)  │
          │    - Ligelizumab (next-gen anti-IgE)        │
          │                                             │
          │  • Short-course ORAL PREDNISOLONE           │
          │    20-40 mg OD for 3-7 days (acute flares)  │
          │    AVOID long-term steroids (adverse effects│
          │    outweigh benefits) [5,6]                 │
          └─────────────────────────────────────────────┘

First-Line Treatment: Non-Sedating H1-Antihistamines

Rationale: Histamine is the primary mediator. H1-receptor antagonism reduces wheals, erythema, and pruritus. [5,6]

Choice of Antihistamine:

Practical Points:

• All agents equally effective at standard doses (no clear superiority in head-to-head trials).
• Individual variation: If one agent ineffective, trial different sgAH before escalating dose.
• Avoid sedating first-generation antihistamines (chlorphenamine, hydroxyzine, promethazine) as first-line due to anticholinergic effects, sedation, cognitive impairment, and tachyphylaxis. May use short-term at night for severe sleep disturbance in selected cases.

Timing: Regular daily dosing (not "as required"). Urticaria is chronic; prophylactic therapy more effective than reactive treatment.

Duration: Continue until symptom-free for 3-6 months, then attempt tapering/discontinuation. Relapse rate ~20-50% within 6 months of stopping.

Dose Escalation: Up to 4× Licensed Dose

Evidence: International EAACI/GA²LEN/EDF/WAO guidelines endorse increasing sgAH dose up to 4× the standard licensed dose for inadequate control. [5,6]

Rationale:

• Standard doses achieve subtherapeutic H1-receptor occupancy in many patients.
• Higher doses increase receptor saturation without significant increase in adverse effects.
• Randomised trials demonstrate superior efficacy vs. standard dose. [17]

Examples:

• Cetirizine 10 mg → 20 mg → 30 mg → 40 mg daily (divided or single dose).
• Fexofenadine 180 mg → 360 mg → 540 mg → 720 mg daily.
• Levocetirizine 5 mg → 10 mg → 15 mg → 20 mg daily.

Practical Approach:

1. Start standard dose. Review at 2-4 weeks.
2. If inadequate control (UAS7 ≥7), double the dose. Review 2-4 weeks.
3. Continue escalating to maximum 4× dose if needed.
4. Maintain maximum dose for 2-4 weeks before deeming treatment failure and advancing to second-line therapy.

Off-Label Use: Dose escalation > 1× licensed dose is off-label in most jurisdictions but explicitly endorsed by international guidelines and considered standard practice. [5,6]

Safety: Excellent safety profile even at 4× dose. Minimal increase in adverse effects (slight increase in sedation with cetirizine/levocetirizine; fexofenadine remains non-sedating). No QT prolongation at recommended doses.

Adjunctive First-Line Options (Modest Evidence)

H2-Antihistamines (Weak Evidence)

• Rationale: H2 receptors contribute to vasodilation.
• Agents: Ranitidine 150 mg BD (NOTE: withdrawn in many countries due to NDMA contamination; alternative: Famotidine 20 mg BD), Cimetidine 400 mg BD.
• Evidence: Limited RCT data. Small benefit when added to H1-antihistamines in refractory cases. [18]
• Current Practice: Rarely used; omalizumab far more effective.

Leukotriene Receptor Antagonists (LTRAs)

• Agent: Montelukast 10 mg OD.
• Rationale: Leukotrienes contribute to vascular permeability and inflammation.
• Evidence: Meta-analyses show modest benefit as add-on to H1-antihistamines. Subgroup of patients (especially those with NSAID-exacerbated urticaria or aspirin sensitivity) may respond better. [19]
• Role: Can trial for 4 weeks in antihistamine-refractory cases before omalizumab, but response rates low (~30%).
• Safety: Generally well-tolerated. Rare neuropsychiatric effects (monitor mood changes).

Second-Line Treatment: Omalizumab (Anti-IgE Monoclonal Antibody)

Omalizumab (Xolair®) is a recombinant humanised anti-IgE monoclonal antibody that binds circulating IgE, preventing IgE-FcεRI interaction. [7,8]

Indications:

• Chronic spontaneous urticaria inadequately controlled by H1-antihistamines (including up-dosed sgAH).
• Licensed for CSU in patients ≥12 years (some countries ≥6 years).

Dosing:

• 300 mg subcutaneously every 4 weeks (fixed dose for CSU, regardless of IgE level or body weight).
• Administer in specialist setting (initial doses) due to rare anaphylaxis risk (less than 0.2%).

Efficacy:

• Landmark RCTs (ASTERIA I, II, GLACIAL): 70-80% of patients achieve significant symptom reduction. [7,14]
• Complete response (UAS7 = 0): 40-50% at 300 mg dose.
• Onset: Typically 1-4 weeks (some patients respond within days; others require 12 weeks).
• Dose-response: 300 mg superior to 150 mg; 150 mg superior to placebo. Higher doses (450-600 mg) used off-label for non-responders but limited evidence.

Duration of Therapy:

• Continue until sustained remission (often 6-12 months minimum).
• Attempt treatment-free period after prolonged control.
• Relapse rate: ~50% relapse within 6-12 months of stopping. Many patients require long-term maintenance therapy.

Safety:

• Excellent safety profile: Headache (most common), injection site reactions, arthralgia.
• Anaphylaxis: Rare (less than 0.2%), typically within first 3 doses. Observe patients 2 hours after first 3 injections; 30 minutes for subsequent doses.
• Long-term safety: Data up to 5+ years show sustained safety.
• No immunosuppression: Does not increase infection risk.

Monitoring: No routine laboratory monitoring required. Assess clinical response (UAS7) at 4-week intervals.

Predictors of Response: No reliable biomarkers. Higher baseline IgE levels may associate with better response, but not sufficiently to guide treatment.

Third-Line and Refractory CSU

Ciclosporin

• Mechanism: Calcineurin inhibitor; inhibits T-cell activation and cytokine production. Reduces mast cell and basophil activation.
• Dosing: 3-5 mg/kg/day in 2 divided doses (typically start 3 mg/kg/day).
• Efficacy: 60-70% response rate in omalizumab-refractory or intolerant patients. [20]
• Onset: 2-4 weeks.
• Duration: Typically 3-6 months (shortest effective duration due to toxicity). Attempt taper after response.
• Adverse Effects: Nephrotoxicity (dose-dependent, usually reversible), hypertension, hypertrichosis, gingival hyperplasia, tremor, increased infection risk, hyperlipidaemia, increased risk of skin malignancies (long-term use).
• Monitoring: Baseline and monthly: serum creatinine, eGFR, BP, lipid profile, FBC, LFTs. Drug level monitoring not routinely required for urticaria.
• Contraindications: Uncontrolled hypertension, renal impairment, malignancy, pregnancy.
• Role: Specialist use only. Reserved for severe, refractory CSU unresponsive to omalizumab.

Emerging Therapies

Corticosteroids

• Short-course oral prednisolone (20-40 mg OD for 3-7 days) can be used for acute severe flares to rapidly control symptoms while initiating/optimising long-term therapy.
• Long-term systemic steroids are NOT recommended due to adverse effects (weight gain, osteoporosis, diabetes, hypertension, immunosuppression, adrenal suppression) outweighing benefits. [5,6]
• Exception: Very rare patients with severe refractory disease may require low-dose maintenance steroids as bridge therapy, but every effort should be made to find steroid-sparing alternatives (omalizumab, ciclosporin).

Management of Chronic Inducible Urticaria (CIndU)

General approach combines trigger avoidance and pharmacotherapy.

Trigger Avoidance Strategies

Pharmacotherapy for CIndU

1. Non-sedating H1-antihistamines (up-dosed as per CSU): First-line for all CIndU subtypes. [5,6]
2. Omalizumab: Increasingly used for refractory CIndU with excellent efficacy (especially cold, cholinergic, solar urticaria). [21]
3. Specific measures:
   • Delayed pressure urticaria: Often most refractory. May require ciclosporin, dapsone, or systemic steroids.
   • Solar urticaria: Phototherapy (PUVA, narrow-band UVB) for desensitisation. Omalizumab highly effective.
   • Cold urticaria: Prophylactic high-dose antihistamines before cold exposure.

Special Populations

Pregnancy and Lactation

• H1-Antihistamines: Cetirizine, loratadine, and fexofenadine considered safe in pregnancy (category B). First-generation antihistamines (chlorphenamine, diphenhydramine) have longest safety data.
• Omalizumab: Limited human data. Pregnancy category B. Use if benefits outweigh risks.
• Ciclosporin: Category C (teratogenic in animals). Avoid if possible; used in severe refractory cases with specialist oversight.
• Prednisolone: Short courses acceptable if necessary (minimal placental transfer before 3rd trimester).

Paediatric Urticaria

• Acute urticaria very common in children (often viral).
• CSU less common but can be highly debilitating.
• Omalizumab licensed ≥12 years for CSU (≥6 years in some jurisdictions). Evidence supports efficacy and safety in children. [22]
• Dose adjustment of antihistamines by age/weight.

---

8. Complications

---

9. Prognosis and Outcomes

Natural History

• Acute Urticaria: Excellent prognosis. Majority resolve within 7-14 days. Recurrent acute episodes occur in ~20%.

• Chronic Spontaneous Urticaria:

  • "Median duration: 2-5 years. [11]"
  • "Remission rates: ~30-50% remit within 1 year; ~50% within 3 years; ~70% within 5 years."
  • "Prolonged disease (> 5 years): 10-20% of CSU patients. Predictors: severe disease, angioedema, positive ASST, thyroid autoimmunity."
  • "Relapsing-remitting course: Common. Spontaneous remissions and exacerbations occur unpredictably."

• Chronic Inducible Urticaria: Variable by subtype.

  • "Symptomatic dermographism: Often persists for years but may spontaneously resolve."
  • "Cholinergic urticaria: May improve or resolve in adulthood."
  • "Cold urticaria: Can persist lifelong. 20% experience anaphylaxis with cold water immersion."
  • "Delayed pressure urticaria: Most refractory; often requires prolonged treatment."

Prognostic Factors

Favourable Prognosis (Earlier Remission):

• Mild disease (low UAS7).
• Absence of angioedema.
• Negative ASST (non-autoimmune CSU).
• Shorter disease duration at presentation.
• Response to first-line antihistamines.

Unfavourable Prognosis (Prolonged Disease):

• Severe disease (UAS7 > 28).
• Presence of angioedema.
• Positive ASST (autoimmune CSU). [3]
• Associated thyroid autoimmunity.
• Coexistent CIndU (CSU + physical urticaria).
• Requirement for high-dose antihistamines or omalizumab.

Treatment Outcomes

• First-line antihistamines: 40-50% achieve control at standard dose; additional 20-30% respond to up-dosing (total ~70% controlled with sgAH). [5,6]
• Omalizumab: 70-80% achieve significant improvement; 40-50% complete response. [7,8]
• Ciclosporin: 60-70% response in omalizumab-refractory patients. [20]
• Relapse after treatment cessation: 50% relapse within 6-12 months of stopping omalizumab; many require long-term maintenance.

Long-Term Outcomes

• No long-term organ damage: Urticaria does not cause scarring or permanent skin changes (unlike vasculitis).
• Psychological impact: Significant anxiety and depression in 30-50% of CSU patients; often improves with disease control.
• Progression to systemic disease: Rare. Urticarial vasculitis may indicate underlying SLE or other connective tissue disease (requires monitoring).

---

10. Prevention and Prophylaxis

Primary Prevention

• Allergen avoidance: If clear allergic trigger identified (food, drug), strict avoidance prevents recurrence.
• Infection prevention: Viral infections are common triggers for acute urticaria (especially children); good hygiene may reduce incidence.
• Medication review: Avoid NSAIDs in NSAID-sensitive urticaria patients. Avoid ACE inhibitors in those with history of angioedema.

Secondary Prevention (Reducing Exacerbations in CSU)

• Regular prophylactic antihistamines: Daily dosing (not as-required) provides stable mast cell suppression.
• Trigger avoidance in CIndU: As detailed above (cold, pressure, heat, sunlight).
• Stress management: Psychological stress can exacerbate urticaria; relaxation techniques, CBT may help.
• Avoid exacerbating factors: Alcohol (vasodilator), tight clothing (pressure), hot baths (heat).

Tertiary Prevention (Preventing Complications)

• Angioedema monitoring: Patients with history of angioedema should be educated on red flags (dysphagia, dysphonia, stridor) and seek immediate medical attention.
• Adrenaline auto-injector (AAI): Prescribe for:
  • History of anaphylaxis.
  • Severe cold urticaria (risk of anaphylaxis with cold water immersion).
  • Recurrent severe angioedema with systemic symptoms.
• Patient education: Provide written action plan. Emphasise importance of adherence to prophylactic antihistamines.

---

11. Evidence and Guidelines

Key Guidelines

Landmark Studies

Evidence Levels

• H1-antihistamines (standard dose): Level I evidence (multiple RCTs, meta-analyses).
• H1-antihistamines (up-dosing to 4×): Level I evidence (RCTs demonstrate superiority vs. standard dose). [17]
• Omalizumab: Level I evidence (multiple large RCTs in CSU). [7,8,14]
• Ciclosporin: Level II evidence (small RCTs, observational studies). [20]
• Leukotriene antagonists: Level II evidence (modest benefit in meta-analyses). [19]
• H2-antihistamines: Level III evidence (limited small studies, conflicting results). [18]

---

12. Patient and Layperson Explanation

What is Urticaria (Hives)?

Urticaria—commonly called "hives"—is a skin condition where you develop itchy, raised, red bumps (called "wheals") on your skin. These bumps can appear anywhere on your body and usually come and go quite quickly: each individual bump typically lasts less than 24 hours before disappearing completely without leaving any mark.

The wheals are caused by a substance called histamine being released from cells in your skin. This causes tiny blood vessels to leak fluid into the surrounding skin, creating the raised, swollen bumps.

What causes urticaria?

Urticaria is divided into acute (lasting less than 6 weeks) and chronic (lasting 6 weeks or longer).

Acute urticaria is very common and often caused by:

• Viral infections (like a cold or flu)—the most common cause in children
• Allergic reactions to foods (nuts, eggs, shellfish, milk) or medications (penicillin antibiotics, aspirin)
• Sometimes no cause is found (about 40-50% of cases)

Chronic urticaria is less common. In most cases (70-80%), it's called Chronic Spontaneous Urticaria (CSU), where the hives appear without any obvious trigger. This is often due to your immune system mistakenly activating the cells that release histamine. In the remaining cases, physical factors like cold, heat, pressure, or sunlight trigger the hives (Chronic Inducible Urticaria).

Is it serious?

Most of the time, urticaria is uncomfortable but not dangerous. However, you should seek immediate medical help (call 999 or go to A&E) if:

• Your lips, tongue, or throat swell significantly
• You have difficulty breathing or swallowing
• You feel dizzy, faint, or develop chest tightness

These symptoms suggest a severe allergic reaction called anaphylaxis, which is a medical emergency requiring urgent treatment with adrenaline.

How is urticaria treated?

For acute urticaria: Most cases get better on their own within a few days to weeks. Antihistamine tablets (like cetirizine or fexofenadine) help reduce the itching and bumps while you recover.

For chronic urticaria: Treatment is a step-by-step approach:

1. First step: Non-sedating antihistamine tablets taken every day (not just when you have symptoms). Common ones include cetirizine, fexofenadine, or loratadine.

2. If that doesn't work: Your doctor can increase the dose of antihistamine—sometimes up to 4 times the normal dose. This is safe and often helps.

3. If high-dose antihistamines don't control your symptoms: You may be referred to a specialist (dermatologist or allergy doctor) who can offer an injection called omalizumab (Xolair). This is given every 4 weeks and works very well for most people with chronic urticaria—about 70-80% of patients see significant improvement.

4. If omalizumab doesn't work: There are other specialist treatments available, such as ciclosporin (an immunosuppressant tablet).

Steroids: Short courses of steroid tablets (like prednisolone) are sometimes used for severe flare-ups to quickly calm things down, but they're not suitable for long-term use due to side effects.

Will it go away?

• Acute urticaria usually clears up within days to weeks.
• Chronic urticaria is more variable. About half of people find their symptoms go away within 1-3 years, but some people have symptoms for longer. The good news is that even if it doesn't go away completely, modern treatments (like omalizumab) can control the symptoms very effectively.

What can I do to help myself?

• Take your antihistamines every day as prescribed, even when you don't have symptoms (this prevents the hives from coming back).
• Avoid known triggers if you've identified any (e.g., certain foods, medications, or physical factors like extreme cold or tight clothing).
• Avoid scratching: This can make the hives worse. Keep your skin cool with a damp cloth or use a moisturiser to soothe itching.
• Manage stress: Stress can sometimes make urticaria worse, so relaxation techniques may help.
• Avoid NSAIDs (like ibuprofen or aspirin) if these seem to make your urticaria worse (affects about 20-30% of people with chronic urticaria). Use paracetamol instead.

Key message

Urticaria can be very frustrating and uncomfortable, but it's usually not dangerous and can be well-controlled with treatment. If you have chronic urticaria that isn't responding to standard antihistamines, ask your GP to refer you to a specialist—there are highly effective treatments available.

---

13. Examination Focus

High-Yield Exam Points

Viva Questions and Model Answers

Q1: How do you distinguish urticaria from urticarial vasculitis?

Model Answer:

Urticarial vasculitis is a distinct entity from simple urticaria, requiring a high index of suspicion:

Key management difference: Urticarial vasculitis requires investigation for underlying systemic disease (SLE, Sjögren's, hepatitis, malignancy) and may need immunosuppression (corticosteroids, colchicine, dapsone, hydroxychloroquine) rather than antihistamines.

---

Q2: A 35-year-old woman with chronic spontaneous urticaria has failed to respond to 4× dose cetirizine (40 mg/day). What is the next step?

Model Answer:

The next step is omalizumab (anti-IgE monoclonal antibody), which is the guideline-endorsed second-line therapy for antihistamine-refractory CSU. [5,6,7]

Dosing: Omalizumab 300 mg subcutaneously every 4 weeks.

Efficacy: 70-80% of patients achieve significant symptom control; 40-50% achieve complete response (UAS7=0).

Mechanism: Omalizumab binds free circulating IgE, preventing IgE from binding to FcεRI on mast cells and basophils. This downregulates FcεRI expression (50-97% reduction), raising the threshold for mast cell degranulation. In autoimmune CSU (anti-IgE or anti-FcεRI antibodies), omalizumab removes IgE from mast cell surfaces, eliminating targets for autoantibodies.

Onset: Typically 1-4 weeks (range: days to 12 weeks).

Safety: Excellent. Main adverse effects are headache and injection site reactions. Anaphylaxis is rare (less than 0.2%). Long-term safety demonstrated over 5+ years.

Monitoring: Clinical response (UAS7 score). No routine laboratory monitoring required.

Alternative: If omalizumab unavailable or contraindicated, consider ciclosporin 3-5 mg/kg/day (off-label, requires close monitoring for nephrotoxicity and hypertension).

Avoid: Long-term systemic corticosteroids (adverse effects outweigh benefits).

---

Q3: Describe the autologous serum skin test (ASST). What does a positive result indicate?

Model Answer:

The autologous serum skin test (ASST) is a bedside provocation test to detect functional histamine-releasing autoantibodies in chronic spontaneous urticaria.

Procedure:

1. Collect 3-5 mL venous blood in plain tube without anticoagulant.
2. Allow to clot; centrifuge to separate serum.
3. Perform intradermal injections on volar forearm:
   • Test: 0.05 mL autologous serum
   • Negative control: 0.05 mL sterile saline
   • Positive control: 0.05 mL histamine (10 mg/mL)
4. Read at 30 minutes. Measure wheal diameters.

Positive Result: Wheal diameter from autologous serum ≥1.5 mm larger than saline control.

Interpretation:

• Indicates presence of functional histamine-releasing factors in serum (typically IgG autoantibodies against IgE or FcεRI).
• Suggests autoimmune CSU (Type I or IIb).
• Sensitivity ~70%; specificity ~80%.

Limitations:

• Does not distinguish between anti-IgE and anti-FcεRI antibodies.
• Can be positive due to non-specific histamine-releasing factors (complement activation, cytokines).
• Does not change routine management (all CSU treated similarly regardless of ASST result).
• Primarily research/specialist tool; not required for diagnosis or treatment decisions in most settings.

Clinical Relevance: Positive ASST may indicate:

• Higher disease severity.
• Longer disease duration.
• Greater likelihood of requiring advanced therapies (omalizumab, ciclosporin).
• Association with thyroid autoimmunity.

---

Q4: What is the UAS7 score and how is it used?

Model Answer:

The Urticaria Activity Score over 7 days (UAS7) is a validated patient-reported outcome measure used to quantify disease severity in chronic spontaneous urticaria. [15]

Scoring System (daily):

• Wheals (0-3 points):

  • 0 = None
  • 1 = Mild (less than 20 wheals/24h)
  • 2 = Moderate (20-50 wheals/24h)
  • 3 = Severe (> 50 wheals/24h or large confluent areas)

• Pruritus intensity (0-3 points):

  • 0 = None
  • 1 = Mild (present but not annoying/troublesome)
  • 2 = Moderate (troublesome but does not interfere with daily activity or sleep)
  • 3 = Severe (interferes with normal daily activity or sleep)

Total: Sum daily scores (wheals + pruritus) over 7 consecutive days. Range: 0-42.

Interpretation:

• 0: Urticaria-free
• 1-6: Well-controlled
• 7-15: Mild activity
• 16-27: Moderate activity
• 28-42: Severe activity

Clinical Applications:

1. Baseline assessment: Quantify disease severity before treatment.
2. Treatment monitoring: Track response to therapy. Assess at regular intervals (e.g., 4-weekly during omalizumab).
3. Treatment goals: Aim for UAS7 less than 7 (ideally 0).
4. Treatment escalation: UAS7 ≥7 despite maximal antihistamines → consider omalizumab.
5. Clinical trials: Primary endpoint in most CSU RCTs.

Advantages: Simple, patient-completed, validated, reproducible. Correlates well with quality of life measures (DLQI, CU-Q2oL).

---

Q5: A patient with chronic urticaria reports triggering of hives by cold exposure. How do you confirm cold urticaria? What is the main safety concern?

Model Answer:

Diagnosis: Ice Cube Test (Cold Stimulation Test)

Procedure:

1. Place ice cube in thin plastic bag (to avoid direct water contact).
2. Apply to volar forearm for 5 minutes.
3. Remove ice and observe for 10 minutes.

Positive Test: Wheal and erythema develop at test site during rewarming phase (critical: reaction occurs on rewarming, not during cold application).

Interpretation: Positive test confirms cold urticaria (a subtype of chronic inducible urticaria).

Variants:

• TempTest®: Standardised device applying graded temperatures (4-44°C) to identify critical temperature threshold.
• Severity grading: Measure time to wheal onset and temperature threshold (shorter time/higher threshold = more severe).

Main Safety Concern: Anaphylaxis Risk

• Cold water immersion (swimming, diving) can trigger systemic cold urticaria → generalised mast cell degranulation → anaphylaxis.
• Risk of drowning if anaphylaxis occurs in water.
• Estimated 20% of cold urticaria patients experience systemic reactions. [5]

Management:

1. Educate patient: Avoid cold water swimming. Avoid sudden whole-body cold exposure.
2. Prophylactic antihistamines: High-dose non-sedating H1-antihistamines before anticipated cold exposure.
3. Prescribe adrenaline auto-injector (AAI): For patients with severe cold urticaria or history of systemic reaction.
4. Omalizumab: Highly effective for refractory cold urticaria (70-80% response). [21]
5. Medical alert bracelet: Consider if severe.

Differential: Exclude secondary causes of cold urticaria (rare):

• Cryoglobulinaemia (hepatitis C, lymphoproliferative disorders)
• Cold agglutinins (Mycoplasma, mononucleosis)
• Cryofibrinogenaemia

---

Clinical Examination Scenario

Scenario: 28-year-old woman presents with widespread itchy rash. Examine the patient and present your findings.

Examination Approach:

1. Inspection:

   • Widespread erythematous, oedematous, raised plaques (wheals) on trunk and limbs.
   • Variable size (1-10 cm); annular/polycyclic configurations.
   • No vesicles, pustules, or scales.
   • Mark a wheal with pen (to assess duration).

2. Palpation:

   • Wheals are raised, firm, oedematous.
   • Diascopy (press glass slide on lesion): Complete blanching → excludes purpura.

3. Dermographism test:

   • Stroke forearm firmly with tongue depressor.
   • Observe for 5 minutes.
   • Positive: Linear wheal develops along stroke line (symptomatic dermographism).

4. Assess for angioedema:

   • Inspect lips, periorbital areas, tongue, hands, feet.
   • Ask about swelling.

5. Exclude alternative diagnoses:

   • No target lesions (erythema multiforme).
   • No fixed pigmented lesions (mastocytosis).
   • Wheals are transient (less than 24h each) → excludes urticarial vasculitis.

Presentation:

"This 28-year-old woman has widespread urticaria. There are multiple erythematous, oedematous, blanching wheals on the trunk and limbs, with annular and polycyclic configurations. Dermographism test is positive, indicating symptomatic dermographism. There is no angioedema, and no features to suggest urticarial vasculitis (lesions are pruritic rather than painful, fully blanching, and individual wheals resolve within 24 hours). I would take a detailed history to determine whether this is acute or chronic urticaria and identify potential triggers."

---

14. References

Primary Sources

1. Kaplan A, Giménez-Arnau AM, Saini SS. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389-401. doi:10.1111/all.15603

2. Lee R,(Rand) Alhusayen R, Bauer A, et al. Chronic spontaneous urticaria and chronic inducible urticaria. J Allergy Clin Immunol. 2025;156(3):571-588. doi:10.1016/j.jaci.2025.05.019

3. Bernstein JA, Kavati A, Tharp MD, et al. BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1219-1232. doi:10.1016/j.jaci.2023.12.008

4. Radonjic-Hoesli S, Hofmeier KS, Micaletto S, et al. Urticaria and Angioedema: an Update on Classification and Pathogenesis. Clin Rev Allergy Immunol. 2018;54(1):88-101. doi:10.1007/s12016-017-8628-1

5. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090

6. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. doi:10.1111/cea.12494

7. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935. doi:10.1056/NEJMoa1215372

8. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306

9. Agache I, Rocha C, Beltran J, et al. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy. 2022;77(1):17-38. doi:10.1111/all.15030

10. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. doi:10.1111/all.13397

11. Maurer M, Magerl M, Metz M, et al. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges. 2013;11(10):971-977. doi:10.1111/ddg.12194

12. Davis MDP, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am. 2004;24(2):183-213. doi:10.1016/j.iac.2004.01.008

13. Pedrosa M, Phillips-Angles E, Morais-Almeida M, et al. Management of angioedema without urticaria in the emergency department. Ann Med. 2014;46(8):607-614. doi:10.3109/07853890.2014.949300

14. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109. doi:10.1016/j.jaci.2013.05.013

15. Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity Score—Validity, Reliability, and Responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-1190.e1. doi:10.1016/j.jaip.2017.10.001

16. Jain V, Patel R, Bansal A, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol. 2024;153(2):456-465. doi:10.1016/j.jaci.2023.10.007

17. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036

18. Yap YY, Tan NH, Koh MJA. Histamine-2 receptor antagonists as add-on therapy to H1-antihistamines in chronic urticaria: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(8):1434-1440. doi:10.1111/jdv.15552

19. Di Lorenzo G, Pacor ML, Pelitteri ME, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114(3):619-625. doi:10.1016/j.jaci.2004.06.018

20. Grattan CEH, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol. 2000;143(2):365-372. doi:10.1046/j.1365-2133.2000.03664.x

21. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and safe treatment of patients with chronic spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomised, double-blind, placebo-controlled study. Br J Dermatol. 2014;171(6):1434-1441. doi:10.1111/bjd.13190

22. Caffarelli C, Cuomo B, Cardinale F, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101. doi:10.1186/s13052-019-0695-x

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions must be individualised based on patient-specific circumstances, local guidelines, and current evidence. Always consult appropriate specialists and use clinical judgment. This content does not constitute medical advice and should not replace professional clinical assessment.